Kriya Therapeutics is developing gene therapies for ophthalmology, neurology and metabolic diseases. Despite diversifying to various disease indications, Kriya is using the same principles to create accessible, specific and effective one-time gene therapies to address common diseases. Kriya’s lead compounds across ophthalmology, neurology and metabolic are all currently in preclinical stages and are employing adeno-associated viruses (AAV) as their delivery modality. For example, Kriya’s approach to treat dry age-related macular degeneration, KRIYA-825, is an AAV gene therapy that encodes a fusion protein to inhibit complement C3 and C5, with the aim of slowing lesion growth and vision loss.

Kriya Therapeutics

Exciting news! We’re proud to announce that we’ve been named one of BioSpace’s 2025 Best Places to Work! This recognition highlights our commitment to fostering a workplace that values collaboration, supports learning, and drives innovation.

A huge thank you to everyone at Kriya who makes our company such a special place to work. We appreciate the recognition of our dedication to building a great company and culture. Here’s to continued growth!
https://bit.ly/4eajevY
  
#biopharma #lifesciences #biospace

 Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight 

Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio - Business Wire

 Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis 

We are excited for this year’s @Alliance for Regenerative Medicine’s 2024 Cell & Gene Meeting on the Mesa, where our President & Chief Operating Officer, Curt Herberts, will be sharing company highlights during a presentation on October 9th at 11:30am MST.

 Kriya unveils new gene therapy KRIYA-586 for thyroid eye disease 

Durham’s Kriya Therapuetics lands $80M to advance gene therapies for diabetes, severe obesity - WRAL TechWire

 Kriya Appoints Katherine Eade as Chief Legal Officer 

Kriya Therapeutics creates chemogenetic approach for trigeminal neuralgia - BioWorld Online

Kriya Raises $270M Series C toward Fully Integrated Gene Therapy Engine - Genetic Engineering and Biotechnology News

Kriya Therapeutics buys scientific advisor’s NASH gene therapy company - Endpoints News

Gene therapy biotech Kriya adds $150M in fresh funds - BioPharma Dive

Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire

ASRS 2023: Russ Trenary, President and CEO at Outlook Therapeutics, shares update on work toward FDA approval for Bevacizumab - Modern Retina

How Xaira Therapeutics' $1B funding raise stacks up - drugdiscoverytrends.com

 Biotech vacancies grow throughout Bay Area, but so does ... 

 Kriya, flush with funding, buys a gene therapy for NASH 

Kriya Appoints Curt Herberts as President and Chief Operating Officer - Business Wire

Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies - Business Wire

Twist's antibodies to wind up with Kriya's AAV gene ...

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio - Business Wire

Kriya relies on M&A toolkit once more to build out gene therapy pipeline, this time in neurology - Fierce Biotech

Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases - Business Wire

 Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf- … 

Kriya adds neurology pipeline to gene therapy portfolio through Redpin Therapeutics acquisition - BioPharma-Reporter.com

Kriya licenses use of Everads’ suprachoroidal delivery device for ocular gene therapy programs - BioWorld MedTech

Kriya raises $100m in Series B funding round to develop gene therapies - Pharmaceutical Technology

 Gene Therapy Co. Taps Experienced Bioscience Legal Chief 

Developers in TED cruise toward phase III days in the sun; Tepezza to feel the chill? - BioWorld Online

Kriya Therapeutics Scores $270 Million to Support Gene Therapy Pipeline - BioSpace

Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer - PR Newswire

 Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf … 

 KRIYA-825 ameliorates retinal degeneration in mice, study shows 

 Developers in TED cruise toward phase III days in the sun; Tepezza to feel the chill? 

Proud to announce new preclinical data in Molecular Therapy demonstrating the potential of our investigational AAV-FGF21 gene therapy (KRIYA-497) for #MASH. Research from Universitat Autonoma de Barcelona (UAB) showed durable reversal of hepatic fibrosis from intramuscular gene therapy, halting liver tumor development in animal models in long-term follow-up. 

Congratulations to Dr. Fátima Bosch and the UAB team! Read more https://bit.ly/48My7mY
  
#GeneTherapy #BiotechNews #LiverDisease #Research 

KRIYA-825 ameliorates retinal degeneration in mice, study shows - BioWorld Online

 Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics 

Kriya grabs $100M to launch gene therapies into the mainstream, starting with diabetes - Fierce Biotech

Join us at the American Society of Gene & Cell Therapy’s 28th Annual Meeting where we’re presenting thirteen abstracts! Data highlights progress across our #genetherapy pipeline in #opthalmology, #metabolicdisease, and #neurology, as well as our core technology and manufacturing capabilities that support our gene therapy platform. #ASGCT2025 Learn more here: https://bit.ly/4jtbsAF


Kriya Therapeutics appoints Pedro Huertas as CMO - Health Tech World

Kriya Therapeutics Completes Renovation of Its Facility for Scalable Gene Therapy Manufacturing - Business Wire

KRIYA-497, a one-time muscle-directed AAV1-FGF21 gene therapy for the treatment of MASH - BioWorld Online

 Durham startup’s $100M fundraiser could help lead to revolution in gene therapies 

www.kriyatx.com/

 Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or … 

 Kriya continues acquisition streak, snapping up gene therapy biotech and diving into the NASH space 

Nine biotech companies to watch in 2024 - Labiotech.eu

Kriya snags $80.5M to push gene therapy beyond rare disease - Fierce Biotech

 Kriya Appoints Curt Herberts as President and Chief Operating Officer 

This Company Raised $100 Million To Bring Gene Therapy To The Masses - Forbes

 Shankar Ramaswamy, M.D.’s Post 

 Kriya Therapeutics creates chemogenetic approach for trigeminal neuralgia 

Kriya Announces the Appointment of Ma’an Muhsin, M.D., as President and Chief Medical Officer of Its Oncology Therapeutic Area Division - Business Wire

4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics - GlobeNewswire

 RTP firm follows up on $150M raise, buys California company 

Kriya Adds Redpin’s Chemogenetics Pipeline to Growing Gene Therapy Portfolio (Updated) - BioSpace

Kriya unveils new gene therapy KRIYA-586 for thyroid eye disease - BioWorld Online

 A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy 

We are excited to share that our Chief Scientific Officer, Michele Stone, Ph.D., PMP, will participate in Nucleate’s Women Leading Life Sciences Virtual Series panel on March 31st at 12pm ET. Join us as Dr. Stone shares her experiences and insights from her journey in the life sciences industry, including her role leading scientific innovation at Kriya Therapeutics.
#WomenInSTEM #LifeSciences #Leadership


Shankar Ramaswamy, MD, on Bringing Gene Therapy to Common Diseases - CGTLive™

Kriya opportunities: Biotech sets up RTP manufacturing facility - BioProcess International

Kriya bags another $150m funding to explore gene therapies - BioProcess Insider

Join us at CGTP Summit 2024 where our Chief Gene Therapy Officer, J Fraser Wright, Ph.D., will share insights on development and manufacturing strategies that impact commercialization during a Q&A session. Click here for more details: https://bit.ly/3CvsNsn.  
#GeneTherapy #BioTech #CGTPSummit2024

Shankar Ramaswamy, M.D. - Fierce Pharma

here

Kriya Appoints Pedro Huertas M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division - Business Wire

 Kriya Therapeutics Scores $270 Million to Support Gene Therapy Pipeline 

2022 Life Sciences Awards: Shankar Ramaswamy with Kriya Therapeutics - The Business Journals

Kriya acquires Redpin Therapeutics, adds gene therapies for epilepsy, trigeminal neuralgia - Healio

 Kriya Therapeutics buys scientific advisor’s NASH gene therapy company 

Twist's antibodies to wind up with Kriya's AAV gene therapies in new pact - Fierce Biotech

Kriya adds $150m to Series C funding round to study gene therapies - Pharmaceutical Technology

Kriya Therapeutics Raises $270M in Series C Financing - FinSMEs

VIDEO: Kriya reviews geographic atrophy, thyroid eye disease gene therapies - Healio

Looking forward to attending the H.C. Wainwright & Co., LLC MASH investor conference today. Hope to see you there! 

Kriya snags $80.5M to push gene therapy beyond rare ...

Article | Inside J.D. Vance’s health care investments - POLITICO Pro

 Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer 

Avfuel & Avflight Executive Elected to NATA Board of Directors - Aviation Pros

Gene therapy company pulls in another $150M to continue scale-up - The Business Journals

Kriya continues acquisition streak, snapping up gene therapy biotech and diving into the NASH space - Fierce Biotech

Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics - Business Wire

Pfizer seeking successor as Dolsten prepares to step down from R&D role - BioCentury

2023 Health Care Leadership Awards: Dr. Shankar Ramaswamy – Kriya Therapeutics - The Business Journals

Join us tomorrow for a fireside chat at RBC Capital Markets Biotechnology Private Company Conference where we’ll share on how we aim to make #genetherapy more accessible to the patients that need it.

 Kriya Therapeutics reports development of KT-A261, AAV2-adalimumab for noninfectious uveitis 

Kriya Therapeutics reports development of KT-A261, AAV2-adalimumab for noninfectious uveitis - BioWorld Online

The Funded: Biotechnology startup Kriya Therapeutics scored $270M funding in the latest Bay Area megadeal - The Business Journals

Kriya Therapeutics Expands Leadership Team with the Appointment of Neera Ravindran, M.D., M.B.A. as Chief Financial Officer - Business Wire

‘Gene therapy redefined:’ Biotech with ops in Durham, California, raises $150M - WRAL TechWire

Biopharmaceutical Kriya acquires Tramontane Therapeutics, a UAB spin-off - UAB Barcelona

Kriya, flush with funding, buys a gene therapy for NASH - BioPharma Dive

KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment - Knowledge Ecology International

Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine - Business Wire

Taking gene therapy to the masses with innovations ...

Kriya’s Rare Disease Division has a New Boss - BioSpace

 Viral vector constructs incorporating dna for inhibiting toll like receptors … 

This #DiabetesAwarenessMonth, we reaffirm our commitment to transforming the treatment of type 1 diabetes and celebrate our dedicated team and fellow researchers who are at the forefront of pioneering innovative solutions for more effective management of this disease.

For the 5 million people in the US and EU living with type 1 diabetes, investing in research is key to improving quality of life and delivering better control of their disease. Discover more about our investigational candidate, Kriya-839, a potential one-time gene therapy for type 1 diabetes: https://bit.ly/4huwzSv
  
#GeneTherapy #Type1Diabetes 


Kriya Therapeutics Appoints Indian American Neera Ravindran Chief Financial Officer - IndiaWest

 Shape of RNA to come: Series Bs boost gene therapy companies 

Kriya Therapeutics

Business:

Drug notes:

About: